- >$1M raised to date, plus $310k on the same terms
- CEO led the 1st clinical trials in the world evaluating exosomes as a treatment for autoimmune disease
- Targeting 25M affected by immune-mediated diseases in US, equal to ~$150B in medical costs/year
- Our intellectual property is patent-protected (patent owned by the Company)
We are applying new knowledge of stem cell biology to develop new treatments for autoimmune diseases.
In 5 years we expect to be close to completing phase III clinical trials for our initial products.